A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Assess the Effect of BIIB014 on the Pharmacokinetics of Rosiglitazone, Warfarin, and Midazolam in Healthy Volunteers

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Assess the Effect of BIIB014 on the Pharmacokinetics of Rosiglitazone, Warfarin, and Midazolam in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 26 May 2016

At a glance

  • Drugs Vipadenant (Primary) ; Midazolam; Rosiglitazone; Warfarin
  • Indications Asthma; Parkinson's disease; Thromboembolism; Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Biogen Idec
  • Most Recent Events

    • 23 Nov 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top